[Role of angiogenesis inhibitors in the treatment of colorectal cancer].
In our time, molecular targeted therapy plays a key role in the modern therapy of solid tumors. Of these modalities, in colorectal cancer monoclonal antibodies are introduced in routine use. In our article we provide an overview of the mechanism of action, place in treatment and efficacy of bevacizumab, an angiogenic inhibitor.
Bodoky
György
G
Fovárosi Szent László és Szent István Kórház, Onkológiai Osztály, Budapest. bodokygy@hungarnet.hu
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068258:Bevacizumab; D002277:Carcinoma / Q000188:drug therapy; D015179:Colorectal Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D006801:Humans; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D011237:Predictive Value of Tests; D040262:Receptors, Vascular Endothelial Growth Factor / Q000187:drug effects; D012307:Risk Factors
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor